Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenit...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Anick Bérard, Shannon Strom, Jin-Ping Zhao, Shashi Kori, Detlef Albrecht
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/8872f81c01f84aba9c5de34e563332be
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!